A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

NCT06994143 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA

Interventions

DRUG: CLN-978

Sponsor

Cullinan Therapeutics Inc.